<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605745</url>
  </required_header>
  <id_info>
    <org_study_id>3034-001</org_study_id>
    <nct_id>NCT03605745</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)</brief_title>
  <acronym>Rezūm XL</acronym>
  <official_title>Minimally Invasive Prostatic Vapor Ablation - Multicenter, Single Arm Study for the Treatment of BPH in Large Prostates (Rezūm XL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, single arm clinical trial designed to evaluate the safety of the&#xD;
      Rezūm System in treating subjects with symptomatic BPH for prostate sizes &gt;80cm3 and ≤150&#xD;
      cm3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, single arm clinical trial designed to evaluate the safety of the&#xD;
      Rezūm System in treating subjects with symptomatic BPH for prostate sizes &gt;80cm3 and ≤150&#xD;
      cm3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decided to terminate the study due to business reasons&#xD;
  </why_stopped>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">August 11, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is a prospective, non-randomized clinical trial of subjects with benign prostatic hypertrophy (BPH).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With ≥ 30% Improvement in Symptoms as Measured by the International Prostate Symptom Score (IPSS)</measure>
    <time_frame>6 Months</time_frame>
    <description>The proportion of the intent-to-treat (ITT) analysis population that responds to the Rezum therapy is reported. A responder is defined as a subject who has an improvement in International Prostate Symptom Score (IPSS) &gt; 30% from baseline to 6 months post-therapy. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Post Procedure Device Related Serious Complications</measure>
    <time_frame>6 Months</time_frame>
    <description>Assess the composite rate of post procedure device related serious complications in treated subjects through 6 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Device-related Retention Catheterizations</measure>
    <time_frame>6 Month</time_frame>
    <description>This safety endpoint will be to characterize the rate of post procedure device-related serious retention catheterizations at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lower Urinary Tract Symptoms as Assessed by the Absolute Change in IPSS Score From Baseline to Follow-up</measure>
    <time_frame>Baseline, 6 weeks, 3 months, 6 months, 1 year</time_frame>
    <description>The change in IPSS from baseline to each follow-up visit was determined. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>BPH With Urinary Obstruction</condition>
  <condition>BPH</condition>
  <condition>BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostatic Vapor Ablation with Rezum</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostatic Vapor Ablation</intervention_name>
    <description>Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rezum</other_name>
    <other_name>Water Vapor Ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects ≥ 50 years of age who have symptomatic BPH.&#xD;
&#xD;
          2. International Prostate Symptom Score (IPSS) score ≥ 13.&#xD;
&#xD;
          3. Peak urinary flow rate (Qmax): ≥ 5ml/sec to ≤ 12 ml/sec with minimum voided volume of&#xD;
             ≥ 125 ml.&#xD;
&#xD;
          4. Post-void residual (PVR) ≤300 ml.&#xD;
&#xD;
          5. Prostate volume &gt;80 cm3 to ≤150 cm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Urology:&#xD;
&#xD;
          1. Any prior invasive prostate intervention (e.g., &quot;Radiofrequency&quot; thermotherapy,&#xD;
             balloon, microwave thermotherapy, &quot;Prostatic Urethral Lift&quot;, &quot;Transurethral&#xD;
             Resection&quot;, or laser) or other surgical interventions of the prostate.&#xD;
&#xD;
          2. Undergone a prostate biopsy within 60 days prior to the scheduled treatment date or&#xD;
             has an imminent need for surgery.&#xD;
&#xD;
          3. Verified acute bacterial prostatitis within last 12 months documented by culture.&#xD;
&#xD;
          4. Active or history of epididymitis within the past 3 months.&#xD;
&#xD;
          5. Urethral strictures, bladder neck contracture, unusual anatomy or muscle spasms that&#xD;
             would prevent the introduction and use of the Rezūm device.&#xD;
&#xD;
          6. Diagnosed bladder, urethral or ureteral stones or active stone passage in the past 6&#xD;
             months, provided that stones that are known to be in the kidney and have been stable&#xD;
             for a period exceeding 3 months are permissible.&#xD;
&#xD;
          7. Subject interested in maintaining fertility.&#xD;
&#xD;
          8. Use of the following medications where the dose is not stable (stable dose defined as&#xD;
             the same medication and dose in the last three months):&#xD;
&#xD;
               1. Beta-blockers;&#xD;
&#xD;
               2. Anticonvulsants;&#xD;
&#xD;
               3. Antispasmodics;&#xD;
&#xD;
               4. Antihistamines;&#xD;
&#xD;
               5. Alpha blockers for BPH and anticholinergics or cholinergics;&#xD;
&#xD;
               6. Type II, 5-alpha reductase inhibitor (e.g., finasteride (Proscar, Propecia));&#xD;
&#xD;
               7. Dual 5-alpha reductase inhibitor (e.g., dutasteride (Avodart));&#xD;
&#xD;
               8. Estrogen, drug-producing androgen suppression, or anabolic steroids;&#xD;
&#xD;
               9. PD5 Inhibitors (e.g., Viagra, Levitra or Cialis)&#xD;
&#xD;
          9. Subjects who have had an incidence of spontaneous urinary retention either treated&#xD;
             with indwelling transurethral catheter or suprapubic catheter 6 months prior to&#xD;
             baseline. A provoked episode now resolved is still admissible&#xD;
&#xD;
         10. Evidence of atonic neurogenic bladder evaluated by a baseline urodynamic assessment.&#xD;
&#xD;
         11. Visible hematuria with subject urine sample without a known contributing factor.&#xD;
&#xD;
         12. Presence of a penile implant or stent(s) in the urethra or prostate&#xD;
&#xD;
         13. Active urinary tract infection by culture within 7 days of treatment or two documented&#xD;
             independent urinary tract infections of any type in the past 6 months.&#xD;
&#xD;
             Gastroenterology:&#xD;
&#xD;
         14. Previous pelvic irradiation or radical pelvic surgery.&#xD;
&#xD;
         15. Previous rectal surgery (other than hemorrhoidectomy) or known history of rectal&#xD;
             disease.&#xD;
&#xD;
             Nephrology:&#xD;
&#xD;
         16. Compromised renal function defined as serum creatinine &gt; 2.0 mg/dl.&#xD;
&#xD;
         17. Hydronephrosis (Grade 2 or higher).&#xD;
&#xD;
             Oncology:&#xD;
&#xD;
         18. Prostate cancer testing:&#xD;
&#xD;
             If PSA is &gt; 2.5 ng/ml and ≤ 10 ng/ml with free PSA &lt;25%, prostate cancer for the&#xD;
             subject must be/had been ruled out through a negative biopsy prior to enrollment&#xD;
&#xD;
               -  Males 50-59 years - PSA is &gt;2.5 ng/ml and ≤10 ng/ml with free PSA &lt;25%,&#xD;
&#xD;
               -  Males 60+ years - PSA is &gt;4 ng/ml and ≤10 ng/ml, with free PSA &lt;25%&#xD;
&#xD;
         19. History of confirmed malignancy or cancer of the prostate or bladder; however, high&#xD;
             grade prostatic intraepithelial &quot;PIN&quot; is acceptable.&#xD;
&#xD;
         20. History of cancer in non-genitourinary system that is not considered cured (except&#xD;
             basal cell or squamous cell carcinoma of the skin). A potential participant is&#xD;
             considered cured if there has been no evidence of cancer within five years of&#xD;
             enrollment.&#xD;
&#xD;
             Cardiology:&#xD;
&#xD;
         21. History of clinically significant congestive heart failure (i.e., NYHA Class III and&#xD;
             IV).&#xD;
&#xD;
         22. Cardiac arrhythmias that are not controlled by medication and/or medical device.&#xD;
&#xD;
         23. An episode of unstable angina pectoris, a myocardial infarction, transient ischemic&#xD;
             attack, or a cerebrovascular accident within the past six months.&#xD;
&#xD;
             Pulmonology:&#xD;
&#xD;
         24. History of significant respiratory disease where hospitalization for the disease is&#xD;
             required.&#xD;
&#xD;
             Hematology:&#xD;
&#xD;
         25. Diagnosed or suspected bleeding disorder, or coagulopathies.&#xD;
&#xD;
         26. Use of antiplatelet or anticoagulant medication except low dose aspirin (&lt;100mg/day)&#xD;
             within 10 days prior to treatment.&#xD;
&#xD;
             Endocrinology:&#xD;
&#xD;
         27. History of diabetes not controlled by a stable dose of medication over the past three&#xD;
             months, provided that patients with a hemoglobin A1c &lt;8.0% are allowed.&#xD;
&#xD;
             Immunology:&#xD;
&#xD;
         28. History of immunosuppressive conditions (e.g., AIDS, post-transplant).&#xD;
&#xD;
             Neurology:&#xD;
&#xD;
         29. Any cognitive or psychiatric condition that interferes with or precludes direct and&#xD;
             accurate communication with the study investigator regarding the study or affect the&#xD;
             ability to complete the study quality of life questionnaires.&#xD;
&#xD;
         30. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or&#xD;
             Parkinson's disease or other neurological diseases known to affect bladder function,&#xD;
             sphincter function or poor detrusor muscle function (&lt; 25% of accepted and established&#xD;
             nomograms).&#xD;
&#xD;
             General:&#xD;
&#xD;
         31. Currently enrolled in any other pre-approval investigational study in the US (does not&#xD;
             apply to long-term post-market studies unless these studies might clinically interfere&#xD;
             with the current study endpoints (e.g., limit use of study-required medication, etc.).&#xD;
&#xD;
         32. Any significant medical history that would pose an unreasonable risk or make the&#xD;
             subject unsuitable for the study.&#xD;
&#xD;
         33. Inability to provide a legally effective &quot;Informed Consent Form&quot; and/or comply with&#xD;
             all the required follow-up requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sydney Adventist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Urology Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Urology, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates, LLC</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology, P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Urology Group</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital/University of Sydney</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <results_first_submitted>June 4, 2021</results_first_submitted>
  <results_first_submitted_qc>July 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>Minimally Invasive</keyword>
  <keyword>Water Vapor Therapy</keyword>
  <keyword>Rezum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03605745/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Months</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Months</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Months</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was terminated for business reasons</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ≥ 30% Improvement in Symptoms as Measured by the International Prostate Symptom Score (IPSS)</title>
        <description>The proportion of the intent-to-treat (ITT) analysis population that responds to the Rezum therapy is reported. A responder is defined as a subject who has an improvement in International Prostate Symptom Score (IPSS) &gt; 30% from baseline to 6 months post-therapy. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
        <time_frame>6 Months</time_frame>
        <population>All subjects enrolled were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ≥ 30% Improvement in Symptoms as Measured by the International Prostate Symptom Score (IPSS)</title>
          <description>The proportion of the intent-to-treat (ITT) analysis population that responds to the Rezum therapy is reported. A responder is defined as a subject who has an improvement in International Prostate Symptom Score (IPSS) &gt; 30% from baseline to 6 months post-therapy. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
          <population>All subjects enrolled were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Post Procedure Device Related Serious Complications</title>
        <description>Assess the composite rate of post procedure device related serious complications in treated subjects through 6 months follow-up.</description>
        <time_frame>6 Months</time_frame>
        <population>All subjects enrolled were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post Procedure Device Related Serious Complications</title>
          <description>Assess the composite rate of post procedure device related serious complications in treated subjects through 6 months follow-up.</description>
          <population>All subjects enrolled were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Device-related Retention Catheterizations</title>
        <description>This safety endpoint will be to characterize the rate of post procedure device-related serious retention catheterizations at 6 months.</description>
        <time_frame>6 Month</time_frame>
        <population>All subjects enrolled were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Device-related Retention Catheterizations</title>
          <description>This safety endpoint will be to characterize the rate of post procedure device-related serious retention catheterizations at 6 months.</description>
          <population>All subjects enrolled were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lower Urinary Tract Symptoms as Assessed by the Absolute Change in IPSS Score From Baseline to Follow-up</title>
        <description>The change in IPSS from baseline to each follow-up visit was determined. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
        <time_frame>Baseline, 6 weeks, 3 months, 6 months, 1 year</time_frame>
        <population>All subjects with data at both baseline and the follow-up visit were included in the analysis (N=47 at 6 weeks, 3 months, 6 months; N=42 at 12 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lower Urinary Tract Symptoms as Assessed by the Absolute Change in IPSS Score From Baseline to Follow-up</title>
          <description>The change in IPSS from baseline to each follow-up visit was determined. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.</description>
          <population>All subjects with data at both baseline and the follow-up visit were included in the analysis (N=47 at 6 weeks, 3 months, 6 months; N=42 at 12 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 6 weeks post-therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.47" lower_limit="-10.49" upper_limit="-6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 3 months post-therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.97" lower_limit="-12.68" upper_limit="-9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 6 months post-therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.62" lower_limit="-13.43" upper_limit="-9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 12 months post-therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.80" lower_limit="-13.57" upper_limit="-10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first patient in until the termination of the study. All 47 subjects were followed to at least the 6- month follow-up visit.</time_frame>
      <desc>For all adverse events related to the device, the procedure, or the disease state being treated, a Clinical Events Committee was utilized for review and adjudication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Prostatic Vapor Ablation with Rezum&#xD;
Prostatic Vapor Ablation: Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.&#xD;
Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <description>Worsening of Right Inguinal Hernia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Prostatitis</sub_title>
                <description>Acute Prostatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bells Palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria Gross with Clots &amp; Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain/Discomfort - Abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sloughing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI - Culture Proven</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Catheter Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria - Gross</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bladder Spasms</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Acute Urinary Retention</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence - Urge</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Poor Stream</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Terminal Dribbling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence - Not Specified</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hesitancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Incomplete Voiding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hematuria - Intermittent Uncomplicated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hematuria Gross with Clots &amp; Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort - Penile</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction - Worsening</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anejaculation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Decrease in Ejaculatory Volume</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hematospermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction - De Novo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain/Discomfort - Pelvic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain/Discomfort - Suprapubic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Retrograde Ejaculation - Confirmed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated by the sponsor for business reasons. As a result there is no patient data presented for the 12 month, 2 year and 3 year follow up visits as they did not occur per termination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kaitlyn Rainbow, Clinical Research Associate</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>952-930-6627</phone>
      <email>kat.rainbow@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

